Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP (CIGMA)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the adjunctive therapy to standard antibiotic treatment of BT086 is safe and effective of decreasing the days patients require endotracheal ventilation due to Severe Community-Acquired Pneumonia (sCAP).
| Condition | Intervention | Phase |
|---|---|---|
|
Community Acquired Pneumonia |
Drug: BT086 Drug: 1% Human Albumin infusion |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP) |
- Ventilator Free Days [ Time Frame: 28 days ] [ Designated as safety issue: No ]VFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.
- 28-day all cause mortality [ Time Frame: 28 days (672 hours from randomization) ] [ Designated as safety issue: No ]All patients will be classified as either "alive at Study Day 28" or, if dead, "dead at Study Day 28", regardless of cause of death.
- 28-day pneumonia-cause mortality [ Time Frame: 28 days (672 hours from randomization) ] [ Designated as safety issue: No ]All patients will be classified as either "alive at Study Day 28" or, if dead, "dead at Study Day 28, with pneumonia as cause of death".
- Time (days) to discharge from ICU [ Time Frame: 28 days ] [ Designated as safety issue: No ]The date and time of admission to and discharge from the ICU will be recorded in the CRF. The time to discharge from the ICU will be calculated as the number of days spent in the ICU.
- Time (days) to discharge from hospital [ Time Frame: 28 days ] [ Designated as safety issue: No ]The date and time of admission to and discharge from the hospital will be recorded in the CRF. The time to discharge from the hospital will be calculated as the number of days spent in the hospital.
- SOFA: Score Sequential Organ Failure Assessment [ Time Frame: 28 days ] [ Designated as safety issue: No ]Each organ system (cardiovascular, haematology, hepatic, renal, respiratory) will be scored using the SOFA methodology.For analysis, a patient will receive a score on each day (Study Days 1-7, Day 14, Day 21, and Day 28). Mean changes in organ function scores over time and percentages of patients whose organ function has resolved will be compared between treatment groups.
- Vasopressor-free days [ Time Frame: 28 days ] [ Designated as safety issue: No ]
Vasopressor-free days will be calculated in a similar manner to VFDs, as described above. Vasopressors include doputamine, epinephrine, dopamine, and norepinephrine.
A day is considered as a vasopressor-free day if a patient does not receive
- Doputamine >2.5 µg/kg/min or/and
- Epinephrine (adrenalin) >=2.5 µg/min or/and
- Dopamine >=2.5 µg/kg/min or/and
- Norepinephrine >=0.014 µg/kg/min for 4 hours per day.
| Estimated Enrollment: | 82 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | September 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: BT086 infusion |
Drug: BT086
BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean IgM content of BT086 which is 23%. Infusion rate: Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period. |
| Placebo Comparator: 1% Human Albumin infusion |
Drug: 1% Human Albumin infusion
1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day. Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached. Treatment will be administered over a 5-day period. Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) |
Detailed Description:
Severe Community-Acquired Pneumonia (sCAP) is usually defined clinically as pneumonia acquired from outside the hospital (CAP) that requires intensive medical care. Mortality of (s)CAP patients admitted to ICU range from 35-58% depending on time and admission of the patient and has not much improved in the last years.
BT086 contains a sufficient number of antibodies against the most frequent pathogens as well as antibodies against lipopolysaccharides and lipid A. Therefore, it can be assumed that administration of BT086 early in the clinical course of a severe infection such as sCAP may provide an effective adjunctive treatment to standard antibiotic therapy for sCAP patients.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Written informed consent:
- given by the patient or
- a legal/authorised representative of the patient or
- a waiver for written informed consent due to emergency situation, in compliance with all local legal requirements.
- Male or female patients aged 18 years or older
- Patient receiving adequate antibiotic treatment for pneumonia
Prior to endotracheal ventilation and therapy, the patient must have at least one of the following two signs of inflammation:
- Fever/Hypothermia Fever defined as an oral temperature of >38°C, tympanic temperature of >38°C or rectal temperature of >38.5°C, or hypothermia (rectal temperature <35.5°C) or
- White blood cell (WBC) count >10,000/mm³ or WBC <4,500/mm³
Patient must have at least one of the following signs and symptoms of pneumonia:
- New or increased cough
- Production of purulent sputum or change in sputum characteristics
- Dyspnoea or tachypnoea (respiratory rate >20 breaths/minute)
- Pleuritic chest pain
- Auscultatory findings on pulmonary examination of rales and/or crackles and/or evidence of pulmonary consolidation (e.g. dullness on percussion, bronchial breath sounds, or egophony)
- Radiological (or other imaging technique) evidence of (an) infiltrate(s) consistent with bacterial pneumonia
- Pneumonia has been acquired outside the hospital. In hospital-admitted patients, pneumonia has been diagnosed a maximum of 72 hours after admission. Patients from nursing homes or similar institutions are eligible.
- Major sCAP criterion: need for endotracheal ventilation
- Treatment of patient with BT086 must start within 12 hours but not earlier than 1 hour after start of endotracheal ventilation
Exclusion Criteria:
- For incapacitated patients: any indication that the patient's presumed will would be against inclusion in the trial
- Patients with suspected hospital-acquired pneumonia
- Severe lung diseases interfering with sCAP therapy e.g. patients with cystic fibrosis,
- Patients receiving Xigris® (drotrecogin alfa, activated Protein C) or medications not approved for sCAP (e.g. Dornase alpha) are excluded from inclusion in the study
- Patients on dialysis
- Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing uncorrectable medical condition).
- Patients unable to be treated due to obesity
- Selective, absolute IgA deficiency with known antibodies to IgA
- Patients with neutrophil count <1,000/mm³ or platelet count <50,000/mm³
- Pregnant or lactating women. A pregnancy test will be performed in all women aged <65 years and the result must be available at study inclusion.
- Known relevant intolerance to immunoglobulins, vaccines or other substances of human origin
- Participation in another interventional clinical trial within 30 days before entering the study or during the study, and/or previous participation in this study (participation in non-interventional trials is allowed).
Contacts and Locations| Contact: Andrea Wartenberg-Demand, MD | ++49 6103 801 ext 497 | wartenberg-demand@biotest.de |
| Contact: Dorothee Schliephake, PhD | ++49 6103 801 ext 9807 | dorothee_schliephake@biotest.de |
| Germany | |
| Universitätsklinikum Halle | Recruiting |
| Halle/Saale, Germany, 06120 | |
| Contact: Hennig Ebelt, MD +49 345-557 ext 2001 hennig.ebelt@medizin.uni-halle.de | |
| Contact: Kathrin Ludwig +49 (0)345 557 ext 2113 kathrin.ludwig@medizin.uni-halle.de | |
| Principal Investigator: Hennig Ebelt, MD | |
| Medizinische Hochschule Hannover | Recruiting |
| Hannover, Germany, 30625 | |
| Contact: Welte Tobias, MD +49 511532 ext 3530 welte.tobias@mh-hannover.de | |
| Contact: Rabea Gatzke +49 511532 ext 3454 gatzke.rabea@mh-hannover.de | |
| Principal Investigator: Tobias Welte, MD | |
| Principal Investigator: | Tobias Welte, MD | Hannover Medical School |
More Information
No publications provided
| Responsible Party: | Biotest |
| ClinicalTrials.gov Identifier: | NCT01420744 History of Changes |
| Other Study ID Numbers: | CIGMA Study 982 |
| Study First Received: | August 19, 2011 |
| Last Updated: | August 19, 2011 |
| Health Authority: | Germany: Paul-Ehrlich-Institut Spain: Agencia Española de Medicamentos y Productos Sanitarios |
Keywords provided by Biotest:
|
Endotracheal ventilation Bacterial pneumonia |
Additional relevant MeSH terms:
|
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on May 22, 2013